Holen Sie sich die Stockscreener-App
8.97
5.04%
0.43
Handel nachbörslich:
8.97
Regenxbio Inc Aktie (RGNX) Neueste Nachrichten
REGENXBIO announces royalty monetization agreement for up to $250M - MSN
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth - Investing.com Australia
REGENXBIO’s SWOT analysis: gene therapy firm’s stock poised for growth By Investing.com - Investing.com South Africa
REGENXBIO’s $250 Million Royalty Bond Agreement with HealthCare Royalty - Global Legal Chronicle
Coave Therapeutics Establishes New Scientific Advisory Board to Accelerate Innovation in Genetic Medicines for Eye and CNS Diseases - GlobeNewswire Inc.
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress - Investing.com Australia
Regenxbio at RBC Conference: Strategic Moves and Clinical Progress By Investing.com - Investing.com Nigeria
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million | RGNX Stock News - GuruFocus
Stifel maintains Buy on Regenxbio, price target at $40 By Investing.com - Investing.com Nigeria
Stifel maintains Buy on Regenxbio, price target at $40 - Investing.com
Regenxbio Secures $250 Million In New Royalty Bonds - Finimize
REGENXBIO secures $150 million to extend cash runway By Investing.com - Investing.com South Africa
Regenxbio (RGNX) Secures $250M Royalty Bond Deal for Non-Dilutiv - GuruFocus
REGENXBIO (RGNX) Secures $250 Million Non-Dilutive Funding - GuruFocus
REGENXBIO secures $150 million to extend cash runway - Investing.com Australia
RegenXBio Secures $250M Royalty Monetization Deal - TipRanks
REGENXBIO Announces Strategic Royalty Monetization Agreement for Up to $250 Million - Eagle-Tribune
Regenxbio Announces Strategic Royalty Monetization Agreement For Up To $250 Million - marketscreener.com
REGENXBIO's $250M Royalty Deal Extends Cash Runway to 2027, Funds Multiple Late-Stage Programs - Stock Titan
Regenxbio signals RGX-202 pivotal enrollment surpasses 50% as company initiates commercial manufacturing in Q3 2025 - MSN
REGENXBIO’s Earnings Call Highlights Strong Start to Fiscal Year - TipRanks
REGENXBIO’s BLA for MPS II Gene Therapy RGX-121 Accepted for Priority Review by the FDA - CGTLive®
REGENXBIO Inc. Just Missed EPS By 64%: Here's What Analysts Think Will Happen Next - simplywall.st
Regenxbio BLA for Hunter syndrome candidate accepted by FDA - MSN
(RGNX) Proactive Strategies - news.stocktradersdaily.com
Earnings Miss: REGENXBIO Inc. Missed EPS By 64% And Analysts Are Revising Their Forecasts - Yahoo Finance
REGENXBIO Inc. (NASDAQ:RGNX) Q1 2025 Earnings Call Transcript - Insider Monkey
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy fo - GuruFocus
FDA Accepts Biologics License Application For Mucopolysaccharidosis II Treatment - marketscreener.com
FDA Grants Priority Review to REGENXBIO's (RGNX) Gene Therapy for MPS II | RGNX Stock News - GuruFocus
FDA Accepts Biologics License Application for Mucopolysaccharidosis II Treatment - Eastern Progress
US FDA accepts Regenxbio’s application for MPS II gene therapy - World Pharmaceutical Frontiers
Earnings call transcript: Regenxbio Q1 2025 misses forecasts, stock rises By Investing.com - Investing.com Nigeria
Stifel maintains buy on Regenxbio, reiterates $40 target - Investing.com Australia
Regenxbio (RGNX) Gains FDA Priority Review for RGX-121 BLA | RGN - GuruFocus
Transcript : REGENXBIO Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 05 - marketscreener.com
Stifel maintains buy on Regenxbio, reiterates $40 target By Investing.com - Investing.com India
REGENXBIO (RGNX) Reports Decrease in Q1 Revenue, Focuses on Gene Therapy Progress | RGNX Stock News - GuruFocus
REGENXBIO Reports First Quarter 2025 Financial Results and Recen - GuruFocus
Regenxbio Says Potential Hunter Syndrome Treatment Granted FDA Priority Review - marketscreener.com
Regenxbio stock rises on FDA’s priority review for MPS II therapy - Investing.com Nigeria
Regenxbio stock rises on FDA’s priority review for MPS II therapy By Investing.com - Investing.com South Africa
Regenxbio Announces FDA Acceptance And Priority Review Of BLA For Rgx-121 For Mps Ii - marketscreener.com
REGENXBIO Announces FDA Acceptance and Priority Review of the BL - GuruFocus
0.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):